Kallikrein-related peptidases (KLKs) and the hallmarks of cancer

References

• Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876–90
   PubMed Web of Science ®Google Scholar
• Sotiropoulou G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem 2009;284:32989–94
   PubMed Web of Science ®Google Scholar
• Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004;2:257–80
   PubMed Web of Science ®Google Scholar
• Sotiropoulou G, Pampalakis G. Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol Sci 2012;33:623–34
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 2004;18:362–5
   PubMed Web of Science ®Google Scholar
• Dhar S, Bhargava R, Yunes M, et al. Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin Cancer Res 2001;7:3393–8
   PubMed Web of Science ®Google Scholar
• Stege R, Grande M, Carlstrom K, et al. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 2000;6:160–5
   PubMed Web of Science ®Google Scholar
• Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 2010;391:505–11
   PubMed Web of Science ®Google Scholar
• Emami N, Diamandis EP. New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family. Mol Oncol 2007;1:269–87
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74
   PubMed Web of Science ®Google Scholar
• Michael IP, Sotiropoulou G, Pampalakis G, et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem 2005;280:14628–35
   PubMed Web of Science ®Google Scholar
• Matsumura M, Bhatt AS, Andress D, et al. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 2005;62:1–13
   PubMed Web of Science ®Google Scholar
• Sutkowski DM, Goode RL, Baniel J, et al. Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst 1999;91:1663–9
   PubMedGoogle Scholar
• Oikonomopoulou K, Diamandis EP, Hollenberg MD. Kallikrein-related peptidases: proteolysis and signalling in cancer, the new frontier. Biol Chem 2010;391:299–310
   PubMed Web of Science ®Google Scholar
• Gratio V, Loriot C, Virca GD, et al. Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signalling pathway in colon cancer cells. Am J Pathol 2011;179:2625–36
   PubMed Web of Science ®Google Scholar
• Ramsay AJ, Dong Y, Hunt ML, et al. Kallikrein-related peptidase 4 (KLK4) initiates intracellular signalling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J Biol Chem 2008;283:12293–304
   PubMed Web of Science ®Google Scholar
• Gratio V, Beaufort N, Seiz L, et al. Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells. Am J Pathol 2010;176:1452–61
   PubMed Web of Science ®Google Scholar
• Mize GJ, Wang W, Takayama TK. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2. Mol Cancer Res 2008;6:1043–51
   PubMed Web of Science ®Google Scholar
• Michel N, Heuze-Vourc'h N, Lavergne E, et al. Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor. Biol Chem 2014;395:1015–25
   PubMed Web of Science ®Google Scholar
• da Costa PL, Sirois P, Tannock IF, Chammas R. The role of kinin receptors in cancer and therapeutic opportunities. Cancer Lett 2014;345:27–38
   PubMed Web of Science ®Google Scholar
• Stewart JM, Gera L, York EJ, et al. Metabolism-resistant bradykinin antagonists: development and applications. Biol Chem 2001;382:37–41
   PubMed Web of Science ®Google Scholar
• Greco S, Storelli C, Marsigliante S. Protein kinase C (PKC)-delta/-epsilon mediate the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin. J Endocrinol 2006;188:79–89
   PubMed Web of Science ®Google Scholar
• Lu Z, Yang Q, Cui M, et al. Tissue kallikrein induces SH-SY5Y cell proliferation via epidermal growth factor receptor and extracellular signal-regulated kinase1/2 pathway. Biochem Biophys Res Commun 2014;446:25–9
   PubMed Web of Science ®Google Scholar
• Shang Z, Niu Y, Cai Q, et al. Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation. Tumour Biol 2014;35:1881–90
   PubMed Web of Science ®Google Scholar
• Jin Y, Qu S, Tesikova M, et al. Molecular circuit involving KLK4 integrates androgen and mTOR signalling in prostate cancer. Proc Natl Acad Sci USA 2013;110:E2572–81
   PubMed Web of Science ®Google Scholar
• Niu Y, Yeh S, Miyamoto H, et al. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 2008;68:7110–19
   PubMed Web of Science ®Google Scholar
• Luo LY, Katsaros D, Scorilas A, et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 2001;7:2372–9
   PubMed Web of Science ®Google Scholar
• Goyal J, Smith KM, Cowan JM, et al. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 1998;58:4782–6
   PubMed Web of Science ®Google Scholar
• Sidiropoulos M, Pampalakis G, Sotiropoulou G, et al. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol 2005;26:324–36
   PubMed Web of Science ®Google Scholar
• Bindukumar B, Schwartz SA, Nair MP, et al. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia 2005;7:241–52
   PubMed Web of Science ®Google Scholar
• Whibley C, Pharoah PDP, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009;9:95–107
   PubMed Web of Science ®Google Scholar
• Morken JD, Packer A, Everett RA, et al. Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method. Cancer Res 2014;74:3673–83
   PubMed Web of Science ®Google Scholar
• Kennedy AR. Chemopreventive agents: protease inhibitors. Pharmacol Ther 1998;78:167–209
   PubMed Web of Science ®Google Scholar
• Ferreira JG, Diniz PM, Andrade de Paula CA, et al. The impaired viability of prostate cancer cell lines by the recombinant plant kallikrein inhibitor. J Biol Chem 2013;288:13641–54
   PubMed Web of Science ®Google Scholar
• Yao Y, Sheng Z, Li Y, et al. Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest 2013;93:577–91
   PubMed Web of Science ®Google Scholar
• Drucker KL, Paulsen AR, Giannini C, et al. Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma. Neuro-Oncology 2013;15:305–18
   PubMed Web of Science ®Google Scholar
• Wang W, Mize GJ, Zhang X, Takayama TK. Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1. Int J Cancer 2010;126:599–610
   PubMed Web of Science ®Google Scholar
• De Lange T. Telomere-related genome instability in cancer. Cold Spring Harb Symp Quant Biol 2005;70:197–204
   PubMedGoogle Scholar
• Mocellin S, Pooley KA, Nitti D. Telomerase and the search for the end of cancer. Trends Mol Med 2013;19:125–33
   PubMed Web of Science ®Google Scholar
• Myers SA, Clements JA. Kallikrein 4 (KLK4), a new member of the human kallikrein gene family is up-regulated by estrogen and progesterone in the human endometrial cancer cell line, KLE. J Clin Endocrinol Metab 2001;86:2323–6
   PubMed Web of Science ®Google Scholar
• Mohajeri A, Zarghami N, Pourhasan Moghadam M, et al. Prostate-specific antigen gene expression and telomerase activity in breast cancer patients: possible relationship to steroid hormone receptors. Oncol Res 2011;19:375–80
   PubMed Web of Science ®Google Scholar
• Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 2011;11:161–76
   PubMed Web of Science ®Google Scholar
• Chesire DR, Isaacs WB. Ligand-dependent inhibition of beta-catenin/TCF signalling by androgen receptor. Oncogene 2002;21:8453–69
   PubMed Web of Science ®Google Scholar
• Gonzalez-Suarez E, Samper E, Flores JM, Blasco MA. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet 2000;26:114–17
   PubMed Web of Science ®Google Scholar
• Gonzalez-Suarez E, Samper E, Ramirez A, et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J 2001;20:2619–30
   PubMed Web of Science ®Google Scholar
• Fan H, Stefkova J, El-Dahr SS. Susceptibility to metanephric apoptosis in bradykinin B2 receptor null mice via the p53-Bax pathway. Am J Physiol Renal Physiol 2006;291:F670–82
   Google Scholar
• Menashi S, Fridman R, Desrivieres S, et al. Regulation of 92-kDa gelatinase B activity in the extracellular matrix by tissue kallikrein. Ann NY Acad Sci 1994;732:466–8
   PubMed Web of Science ®Google Scholar
• Takayama TK, McMullen BA, Nelson PS, et al. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001;40:15341–8
   PubMed Web of Science ®Google Scholar
• Giusti B, Serrati S, Margheri F, et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 2005;52:3618–28
   PubMed Web of Science ®Google Scholar
• Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205–22
   PubMed Web of Science ®Google Scholar
• Guillon-Munos A, Oikonomopoulou K, Michel N, et al. Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors. J Biol Chem 2011;286:25505–18
   PubMed Web of Science ®Google Scholar
• Kodama M, Kitadai Y, Sumida T, et al. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor beta is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci 2010;101:1984–9
   PubMed Web of Science ®Google Scholar
• Schito L, Rey S, Tafani M, et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci USA 2012;109:E2707–16
   PubMed Web of Science ®Google Scholar
• Kryza T, Achard C, Parent C, et al. Angiogenesis stimulated by human kallikrein-related peptidase 12 acting via a platelet-derived growth factor B-dependent paracrine pathway. FASEB J 2014;28:740–51
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ, Balmain A. TGF-beta signalling in tumor suppression and cancer progression. Nat Genet 2001;29:117–29
   PubMed Web of Science ®Google Scholar
• Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999;91:1635–40
   PubMed Web of Science ®Google Scholar
• Saraswati S, Block AS, Davidson MK, et al. Galectin-3 is a substrate for prostate specific antigen (PSA) in human seminal plasma. Prostate 2011;71:197–208
   PubMed Web of Science ®Google Scholar
• Markowska AI, Liu FT, Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med 2010;207:1981–93
   PubMed Web of Science ®Google Scholar
• Zhu B, Lu L, Cai W, et al. Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther 2007;6:3297–306
   PubMed Web of Science ®Google Scholar
• Wright JK, Botha JH, Naidoo S. Influence of the kallikrein-kinin system on prostate and breast tumour angiogenesis. Tumour Biol 2008;29:130–6
   PubMed Web of Science ®Google Scholar
• Colman RW. Regulation of angiogenesis by the kallikrein-kinin system. Curr Pharm Des 2006;12:2599–607
   PubMed Web of Science ®Google Scholar
• Kuhr F, Lowry J, Zhang Y, et al. Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides 2010;44:145–54
   PubMed Web of Science ®Google Scholar
• Guo YL, Colman RW. Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. J Thromb Haemost 2005;3:670–6
   PubMed Web of Science ®Google Scholar
• Colman RW, Wu Y, Liu Y. Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling. Thromb Haemost 2010;104:875–85
   PubMed Web of Science ®Google Scholar
• Kryza T, Lalmanach G, Lavergne M, et al. Pro-angiogenic effect of human kallikrein-related peptidase 12 (KLK12) in lung endothelial cells does not depend on kinin-mediated activation of B2 receptor. Biol Chem 2013;394:385–91
   PubMed Web of Science ®Google Scholar
• Dong Y, Loessner D, Irving-Rodgers H, et al. Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clin Exp Metastasis 2014;31:135–47
   PubMed Web of Science ®Google Scholar
• Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000;291:113–35
   PubMed Web of Science ®Google Scholar
• Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995;1:1089–94
   PubMed Web of Science ®Google Scholar
• Cumming AP, Hopmans SN, Vukmirovic-Popovic S, Duivenvoorden WC. PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo. Prostate Cancer Prostatic Dis 2011;14:286–94
   PubMed Web of Science ®Google Scholar
• Krenzer S, Peterziel H, Mauch C, et al. Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment. J Investig Dermatol 2011;131:2281–8
   PubMed Web of Science ®Google Scholar
• Kapadia C, Ghosh MC, Grass L, Diamandis EP. Human kallikrein 13 involvement in extracellular matrix degradation. Biochem Biophys Res Commun 2004;323:1084–90
   PubMed Web of Science ®Google Scholar
• Chee J, Naran A, Misso NL, et al. Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer. Biol Chem 2008;389:1225–33
   PubMed Web of Science ®Google Scholar
• Stone OA, Richer C, Emanueli C, et al. Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler Thromb Vasc Biol 2009;29:657–64
   PubMed Web of Science ®Google Scholar
• Biyashev D, Tan F, Chen Z, et al. Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am J Physiol Heart Circ Physiol 2006;290:H1244–50
   Google Scholar
• Madeddu P, Emanueli C, El-Dahr S. Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling. Nat Clin Pract Nephrol 2007;3:208–21
   PubMedGoogle Scholar
• Dorn J, Harbeck N, Kates R, et al. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann Oncol 2011;22:877–83
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lyons CE Jr, Xiao A, et al. Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion. Biochem Biophys Res Commun 2008;369:1215–20
   PubMed Web of Science ®Google Scholar
• Ghosh MC, Grass L, Soosaipillai A, et al. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol 2004;25:193–9
   PubMed Web of Science ®Google Scholar
• Ramani VC, Haun RS. The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem Biophys Res Commun 2008;369:1169–73
   PubMed Web of Science ®Google Scholar
• Moss NM, Barbolina MV, Liu Y, et al. Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res 2009;69:7121–9
   PubMed Web of Science ®Google Scholar
• Loessner D, Quent VM, Kraemer J, et al. Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecol Oncol 2012;127:569–78
   PubMed Web of Science ®Google Scholar
• Dong Y, Tan OL, Loessner D, et al. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res 2010;70:2624–33
   PubMed Web of Science ®Google Scholar
• Dong Y, Stephens C, Walpole C, et al. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. PLoS One 2013;8:e57056
   PubMed Web of Science ®Google Scholar
• Pepin D, Shao ZQ, Huppe G, et al. Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model. PLoS One 2011;6:e26075
   PubMed Web of Science ®Google Scholar
• Singh S, Sadacharan S, Su S, et al. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 2003;63:2306–11
   PubMed Web of Science ®Google Scholar
• Veveris-Lowe TL, Lawrence MG, Collard RL, et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 2005;12:631–43
   PubMed Web of Science ®Google Scholar
• Klucky B, Mueller R, Vogt I, et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res 2007;67:8198–206
   PubMed Web of Science ®Google Scholar
• Johnson SK, Ramani VC, Hennings L, Haun RS. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer 2007;109:1811–20
   PubMed Web of Science ®Google Scholar
• Ramani VC, Kaushal GP, Haun RS. Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains. Biochim Biophys Acta 2011;1813:1525–31
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001;12:27–36
   PubMed Web of Science ®Google Scholar
• Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442–54
   PubMed Web of Science ®Google Scholar
• Pampalakis G, Prosnikli E, Agalioti T, et al. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res 2009;69:3779–87
   PubMed Web of Science ®Google Scholar
• Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 2007;1776:22–31
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signalling in T cells. Nat Med 2001;7:1118–22
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Schauber J, Coda A, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006;20:2068–80
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007;13:975–80
   PubMed Web of Science ®Google Scholar
• Oikonomopoulou K, DeAngelis RA, Chen H, et al. Induction of complement C3a receptor responses by kallikrein-related peptidase 14. J Immunol 2013;191:3858–66
   PubMed Web of Science ®Google Scholar
• Karan D. Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen? Immunotherapy 2013;5:907–10
   PubMed Web of Science ®Google Scholar
• Thomas-Kaskel AK, Waller CF, Schultze-Seemann W, Veelken H. Immunotherapy with dendritic cells for prostate cancer. Int J Cancer 2007;121:467–73
   PubMed Web of Science ®Google Scholar
• Wilkinson R, Woods K, D'Rozario R, et al. Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunol Immunother 2012;61:169–79
   PubMed Web of Science ®Google Scholar
• Hural JA, Friedman RS, McNabb A, et al. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J Immunol 2002;169:557–65
   PubMed Web of Science ®Google Scholar
• Karan D, Dubey S, Van Veldhuizen P, et al. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Immunotherapy 2011;3:735–46
   PubMed Web of Science ®Google Scholar
• Lee HY, Yang EG, Park H. Hypoxia enhances the expression of prostate-specific antigen by modifying the quantity and catalytic activity of Jumonji C domain-containing histone demethylases. Carcinogenesis 2013;34:2706–15
   PubMed Web of Science ®Google Scholar
• Greijer AE, van der Groep P, Kemming D, et al. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 2005;206:291–304
   PubMed Web of Science ®Google Scholar
• Bakin RE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of Ras signalling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003;63:1975–80
   PubMed Web of Science ®Google Scholar
• Hawksworth D, Ravindranath L, Chen Y, et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 2010;13:311–15
   PubMed Web of Science ®Google Scholar
• Mayfield RK, Shimojo N, Jaffa AA. Skeletal muscle kallikrein. Potential role in metabolic regulation. Diabetes 1996;45:S20–3
   Google Scholar
• Heiker JT, Kloting N, Kovacs P, et al. Vaspin inhibits kallikrein 7 by serpin mechanism. Cell Mol Life Sci 2013;70:2569–83
   PubMed Web of Science ®Google Scholar
• Pampalakis G, Obasuyi O, Papadodima O, et al. The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway. Oncotarget 2014;5:2390–403
   PubMed Web of Science ®Google Scholar
• Moon JS, Jin WJ, Kwak JH, et al. Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J 2011;433:225–33
   PubMed Web of Science ®Google Scholar
• Saxena P, Trerotola M, Wang T, et al. PSA regulates androgen receptor expression in prostate cancer cells. Prostate 2012;72:769–76
   PubMed Web of Science ®Google Scholar
• Kim JY, Kim do Y, Son H, et al. Protease-activated receptor-2 activates NQO-1 via Nrf2 stabilization in keratinocytes. J Dermatol Sci 2014;74:48–55
   PubMed Web of Science ®Google Scholar
• Chiang WC, Chien CT, Lin WW, et al. Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. Free Radic Biol Med 2006;41:1304–14
   PubMed Web of Science ®Google Scholar
• Casalino-Matsuda SM, Monzon ME, Conner GE, et al. Role of hyaluronan and reactive oxygen species in tissue kallikrein-mediated epidermal growth factor receptor activation in human airways. J Biol Chem 2004;279:21606–16
   PubMed Web of Science ®Google Scholar
• Dai J, Zhu X, Yoder MC, et al. Cleaved high-molecular-weight kininogen accelerates the onset of endothelial progenitor cell senescence by induction of reactive oxygen species. Arterioscler Thromb Vasc Biol 2011;31:883–9
   PubMed Web of Science ®Google Scholar
• Bockmann S, Paegelow I. Kinins and kinin receptors: importance for the activation of leukocytes. J Leukoc Biol 2000;68:587–92
   PubMed Web of Science ®Google Scholar
• Sotiropoulou G, Pampalakis G. Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation. Biol Chem 2010;391:321–31
   PubMed Web of Science ®Google Scholar
• Yu J, Mookherjee N, Wee K, et al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J Immunol 2007;179:7684–91
   PubMed Web of Science ®Google Scholar
• Paliouras M, Diamandis EP. Intracellular signalling pathways regulate hormone-dependent kallikrein gene expression. Tumour Biol 2008;29:63–75
   PubMed Web of Science ®Google Scholar
• Prassas I, Eissa A, Poda G, Diamandis EP. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov 2015;14:183–202
   PubMed Web of Science ®Google Scholar
• Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 2012;320:130–7
   PubMed Web of Science ®Google Scholar
• Roos AK, Pavlenko M, Charo J, et al. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005;62:217–23
   PubMed Web of Science ®Google Scholar
• Fingleton B. MMPs as therapeutic targets – still a viable option? Semin Cell Dev Biol 2008;19:61–8
   PubMed Web of Science ®Google Scholar
• Brenk R, Schipani A, James D, et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. Chem Med Chem 2008;3:435–44
   Web of Science ®Google Scholar
• Shoichet BK. Virtual screening of chemical libraries. Nature 2004;432:862–5
   PubMed Web of Science ®Google Scholar
• Yu Y, Prassas I, Diamandis EP. Putative kallikrein substrates and their (patho)biological functions. Biol Chem 2014;395:931–43
   PubMed Web of Science ®Google Scholar